Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NANT CRC Vaccine in Recurrent or Metastatic CRC
NCT03169777Phase 2Withdrawn
- Sponsor
- ImmunityBio, Inc.
- Start
- Aug 2018
- Primary completion
- Jan 2019
- Modality
- Adenoviral Vectors, DNA Vaccines, Peptide-based Cancer Vaccines
01
Overview
Phase 2, open-label, single-arm trial of nogapendekin alfa inbakicept, haNK, ETBX-011, ETBX-021, ETBX-051 and 4 more in colorectal cancer (CRC), sponsored by ImmunityBio, Inc. Primary endpoints: Incidence of treatment-emergent Adverse Events at 1 year, Objective Response Rate at 1 year and 1 more. Planned start Aug 2018; status: withdrawn.
02
Drugs
nogapendekin alfa inbakicepthaNKETBX-011ETBX-021ETBX-051
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03169777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03169777.